.png?sfvrsn=c3edc68e_6)
Jayantha GUNARATNE
Translational Biomedical Proteomics
PhD – Bioscience, Tokyo Institute of Technology, Japan
Email: jayanthag@imcb.a-star.edu.sg
SUMMARY
Jayantha Gunaratne is a Senior Principal Investigator at the Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR) and Adjunct Faculty at the Yong Loo Lin School of Medicine, National University of Singapore.
When he joined IMCB in 2007, Jayantha was a founder member of IMCB Advanced Proteomics Lab. He pioneered the establishment of Advanced Proteomics Technology in Singapore and initiated a Translational Biomedical and Clinical Proteomics Research Programme at IMCB. Key outcomes of this programme include discovery of novel protein targets for ocular neovascularization and triple negative breast cancer and developing first-of-its-kind clinical mass spectrometry assay for pathogen detections. He also established a large collaborative network of several local and international research institutes, universities, hospitals and government agencies. He has a track record of over 100 publications and several inventions.
Jayantha obtained his PhD in Biosciences from Tokyo Institute of Technology, Japan in 2003. In 2004, he was offered a postgraduate research scholar position at Scripps Institution, University of California San Diego, USA to pursue his postdoctoral work on genome annotation, proteomics and biochemical analysis in developmental biology.
AWARDS
- 2019 Firefly Awards Borderless Award , Ministry of Trade & Industry (MTI), Singapore
- 2019 Borderless Award, A*STAR, Singapore
- 2013 College Day Partners’ Award and Mentorship trophy, National Junior College, Singapore
- 2003 Japanese Young Scientist Awards, Inoue Foundation for Science, Japan & 2001 Yasumasu Foundation, Japan
- 2024: A*STAR Innovative & Enterprise (I&E) GAP funding on Ocular Therapeutics, A*STAR Industry Alignment Fund (IAF) - Industry Collaboration Projects (ICP) on Ocular Therapeutics, National Research Foundation (NRF)-Competitive Research Program (CRP) on Cancer Biology
- 2023: A*STAR I&E GAP funding on Ocular Therapeutics
- 2022: NRF-White Space Grant (Singapore Food Story) on food safety assay
- 2021: A*STAR Health & Medical Technologies – Biomedical Engineering Programme (BEP) on diagnostic MS
- 2020: A*STAR I&E GAP funding on food safety (MALDI assay), A*STAR IAF – Prepositioning (PP) on food nutrition, National Medical Research Council (NMRC) Open Fund – Large Collaborative Grant (OF-LCG) on HBV Functional Cure
- 2019: IAF-ICP on IMCB-Indivumed Cancer Library Initiative
- 2018: A*STAR Advanced Manufacturing and Engineering (AME) Domain’s Strategic fund award on food safety (MALDI assay)
- 2016: NMRC– Translational Clinical Research (TCR) Flagship programme – Tier 2 on HBV biology
- 2015: A*STAR IAF award for IMCB-SCIEX industry programme, BMRC Strategic Programme Fund (SPF) awards (2) – ATTRaCT (cardiovascular) & SIPRAD (Retinal Diseases)
- several NMRC-OF/CSIRG/CSA grants with Co-I roles
RESEARCH
Disease Ectoproteome: Decoding sheddome, surfaceome, matrisome & biofluid proteome for identifying new-age molecular therapeutics & diagnostics.
Diagnostics Assays: Developing assays for disease pathogen and food hazards detection.
- Multiomics analyses reveal dynamic bioenergetic pathways and functional remodeling of the heart during intermittent fasting.
Arumugam TV#, Alli-Shaik A#, Liehn EA, Selvaraji S, Poh L, Rajeev V, Cho Y, Cho Y, Kim J, Kim J, Swa HLF, Hao DTZ, Rattanasopa C, Fann DY, Mayan DC, Ng GY, Baik SH, Mallilankaraman K, Gelderblom M, Drummond GR, Sobey CG, Kennedy BK, Singaraja RR, Mattson MP, Jo DG, Gunaratne J.
Elife. 2023 Sep 28;12:RP89214. doi: 10.7554/eLife.89214. PMID: 37769126; PMCID: PMC10538958
#First authors - System-wide vitreous proteome dissection reveals impaired sheddase activity in diabetic retinopathy.
Alli-Shaik A, Qiu B, Lai SL, Cheung N, Tan G, Neo SP, Tan A, Cheung CMG, Hong W, Wong TY, Wang X, Gunaratne J.
Theranostics. 2022 Sep 11;12(15):6682-6704. doi: 10.7150/thno.72947. PMID: 36185601; PMCID: PMC9516227
Media coverage - https://www.eurekalert.org/news-releases/975209; Worldpharmatoday, Medicalxpress.com, CNA 938Live Radio interview and Journal Cover (https://www.thno.org/v12i15) - Englerin A rewires Phosphosignaling via Hsp27 Hyperphosphorylation to induce cytotoxicity in renal cancer cells.
Neo SP, Alli-Shaik A, Wee S, Lim Z, Gunaratne J.
J Proteome Res. 2022 Aug 5;21(8):1948-1960. doi: 10.1021/acs.jproteome.2c00248. Epub 2022 Jul 15. PMID: 35838755. - Comprehensive proteomic characterization reveals subclass-specific molecular aberrations within triple-negative breast cancer.
Kosok M, Alli-Shaik A, Bay BH, Gunaratne J.z
iScience. 2020 Feb 21;23(2):100868. doi: 10.1016/j.isci.2020.100868. Epub 2020 Jan 28. PMID: 32058975; PMCID: PMC7015993
Featured in Cover in iScience April 2020 issue - https://www.cell.com/iscience/issue?pii=S2589-0042(20)X0004-6 - Multiplex targeted mass spectrometry assay for one-shot flavivirus diagnosis.
Wee S, Alli-Shaik A, Kek R, Swa HLF, Tien WP, Lim VW, Leo YS, Ng LC, Hapuarachchi HC, Gunaratne J.
Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):6754-6759. doi: 10.1073/pnas.1817867116. Epub 2019 Mar 18. PMID: 30886083; PMCID: PMC6452653
Media coverage (US-based Genomeweb 360Dx & EurekAlert!, SG Straits Times, Health Care Today, Lianhe Zaobao and BioSpace) - Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-cateninexpression.
Lim JP, Nair S, Shyamasundar S, Chua PJ, Muniasamy U, Matsumoto K, Gunaratne J*, Bay BH*
Cancer Lett. 2019 Jun 28;452:119-131. doi: 10.1016/j.canlet.2019.03.014. Epub 2019 Mar 21. PMID: 30905819
*Co-corresponding authors
- Bladder carcinoma biomarkers (US10509034B2)
Disclosed are bladder cancer protein biomarkers, methods of determining whether a patient suffers from or shows recurrence of bladder cancer or early-stage bladder cancer, or late-stage bladder cancer using the bladder cancer protein biomarkers, a detection system, and kits thereof. Said bladder cancer biomarkers comprise at least one of Coronin-IA, Apolipoprotein A-IV, Semenogelin-2, Gamma-synuclein and DJ-1, and variants thereof.
A*STAR celebrates International Women's Day
From groundbreaking discoveries to cutting-edge research, our researchers are empowering the next generation of female science, technology, engineering and mathematics (STEM) leaders.
Get inspired by our #WomeninSTEM